Skip to main content

Liver Cancer News

News
02/11/2021
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
Compared with selective internal...
02/11/2021
Journal of Clinical Pathways
News
01/28/2021
Study findings suggest pembrolizumab is not a cost-effective second-line therapy for HCC at its current price in the US.
Study findings suggest pembrolizumab is not a cost-effective second-line therapy for HCC at its current price in the US.
Study findings suggest...
01/28/2021
Journal of Clinical Pathways